Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
- Xeris secures a total facility size of $215M with Hayfin Capital Management LLP.
- The company can draw down $15.2M to redeem outstanding 5.00% convertible senior notes due 2025.
- Borrowing interest rate reduced by 2.05% per year, enhancing cost of capital.
- Increased cash balance by approximately $35M through the refinancing transaction.
- Xeris aims to utilize net proceeds for working capital and general corporate purposes.
- Maturity of the debt facility is set at five (5) years from the closing date.
- Interest rate on the debt facility is 6.95% plus the greater of CME Term SOFR or 2.00% per annum.
- Xeris is entitled to make interest-only payments on a quarterly basis until maturity or prepayment of the loan.
- The company must maintain certain minimum liquidity and revenue requirements during the loan term.
- Hayfin Capital Management LLP expresses confidence in Xeris' growth and product development capabilities.
- None.
Insights
The refinancing transaction completed by Xeris Biopharma Holdings with Hayfin Capital Management is a strategic financial move, indicative of Xeris' ability to negotiate favorable terms amidst a dynamic credit market. The reduction in borrowing interest rate by 2.05% annually reflects positively on Xeris' credit profile and suggests a robust financial position that could potentially lead to cost savings on debt servicing. This move might also resonate well with investors and could influence the company's stock performance, as it demonstrates prudent financial management and operational efficiency.
Furthermore, the upsized facility provides Xeris with an increased cash balance, which enhances the company's liquidity position. This is crucial for a biopharmaceutical company that requires significant capital for research and development activities, as well as for the commercialization of its products. The additional capital availability also offers strategic flexibility, allowing Xeris to potentially accelerate growth initiatives or pursue new opportunities without the immediate pressure of raising additional funds through equity markets, which can be dilutive to existing shareholders.
From a medical research perspective, the increased financial flexibility for Xeris could have substantial implications for the company's research pipeline and product development. The availability of additional working capital is essential for funding ongoing clinical trials, accelerating new drug development and ensuring the successful commercialization of innovative therapies. The ability to draw down an extra $15.2 million to manage convertible notes also indicates a proactive approach to capital structure management, which is critical in the biopharmaceutical industry where the timing of capital needs can be unpredictable due to the regulatory environment and the nature of clinical trial outcomes.
It is also worth noting that the confidence expressed by Hayfin in Xeris' strategy and product market adoption could signal to other stakeholders the potential for future success in the company's pipeline. This could have a positive impact on the company's reputation and credibility within the medical and investment communities, possibly leading to more favorable terms in future financing or strategic partnerships.
Assessing the broader market implications, the amended debt facility for Xeris underscores a positive sentiment in the biopharmaceutical sector regarding the company's growth trajectory. The commitment from Hayfin reflects a vote of confidence not only in Xeris' current financial health but also in its long-term strategy. This deal could serve as a benchmark for similar companies seeking to refinance or secure new debt facilities, indicating a possibly favorable lending environment for well-positioned firms in the healthcare sector.
The reduction in interest expense due to the lower borrowing rate could potentially enhance Xeris' profitability margins, which is a key metric for market analysts when assessing the financial health of a company. As such, this transaction may influence peer comparisons and investment attractiveness within the biopharmaceutical industry. By managing its cost of capital effectively, Xeris sets a precedent for operational excellence that could impact investor sentiment and market valuations in this sector.
Improves cost of capital Increases committed capital to a total facility size of
“We are very pleased with the outcome of this refinancing transaction with Hayfin. This upsized facility, along with cash generation from our existing products and partnerships, allows us greater flexibility to continue to invest in the growth of our business. In addition to the new capital, we reduced our borrowing interest rate by
Under the terms of the new debt facility, Xeris drew down
Andrew Merrill, Managing Director of Healthcare at Hayfin said, “We are pleased to continue to invest in Xeris through this new senior secured loan. Since our initial engagement two years ago, Xeris has demonstrated its ability to develop and bring to market products with clear, valuable benefits to patients, which also garner strong market adoption. These compelling attributes are hallmarks of our lending strategy and give us confidence to continue supporting Xeris’ strong growth.”
Evercore acted as sole financial advisor to Xeris on this transaction.
About Xeris Biopharma Holdings, Inc.
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, a proven therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses, bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect®, and support long-term product development and commercial success.
Xeris Biopharma Holdings is headquartered in
About Hayfin Capital Management LLP
Founded in 2009, Hayfin Capital Management (“Hayfin”) is a leading alternative asset management firm with c.
Hayfin has a diverse international team of over 200 experienced industry professionals with offices globally, including headquarters in
Further information can be found at hayfin.com.
Forward-Looking Statements
Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., including statements regarding plans, projections and estimates regarding the use of proceeds from the amended and restated term loan facility, the timing or likelihood of redeeming an additional debt facility under the amended and restated term loan facility, the further support of Hayfin, and other statements containing the words “will,” “would,” “continue,” “expect,” “should,” “anticipate” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its and collaborators’ ability to protect its intellectual property and proprietary technology. No assurance can be given that such expectations will be realized and persons reading this communication are therefore cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including its most recently filed Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to us, as of the date of this communication and, while we believe our assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, we do not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306343645/en/
Investor Contact:
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: Xeris Biopharma Holdings, Inc.
FAQ
What is the total facility size Xeris secured with Hayfin Capital Management LLP?
How much can Xeris draw down to redeem its outstanding convertible notes?
By how much was Xeris able to reduce its borrowing interest rate?
What is the maturity period of the debt facility secured by Xeris?
What is the interest rate on the debt facility borrowed by Xeris?
What are the requirements Xeris must maintain during the loan term?
Who acted as the financial advisor to Xeris on this transaction?
